Why the study?
Data concerning the link between APOE polymorphism and APOE levels in patients with chronic kidney disease were inconclusive.
Population
90 non-dialysed CKD patients
Comparison
APOE genotype subgroups: E2(ε2ε3) vs E3(ε3ε3) vs E4(ε3ε4)
Design
Observational cross-sectional study
Key result
In patients with chronic kidney disease, APOE serum concentration positively correlated with eGFR in the E2 genotype subgroup (r = 0.7, p < 0.001) but inversely correlated in the E3 subgroup (r = -0.29, p = 0.02).
Authors
Loading...
APOE genotype may modify lipid-renal links in CKD; leaves open implications for CV risk stratification.
Cross-Sectional (n=90)
No
Effect estimate: r = 0.7 (E2 subgroup); r = -0.29 (E3 subgroup)
p-value: p=<0.001 (E2); 0.02 (E3)
In patients with chronic kidney disease, APOE genotype and renal function are significantly associated with APOE concentration and its redistribution among lipoprotein classes, which may influence cardiovascular risk.
Czaplińska et al. (2019) conducted a cross-sectional in Chronic kidney disease (n=90). APOE gene polymorphism (E2, E3, E4 genotypes) vs. Between APOE genotypes was evaluated on Correlation between APOE serum concentration and eGFR (r = 0.7 (E2 subgroup); r = -0.29 (E3 subgroup), p=<0.001 (E2); 0.02 (E3)). In patients with chronic kidney disease, APOE serum concentration positively correlated with eGFR in the E2 genotype subgroup (r = 0.7, p < 0.001) but inversely correlated in the E3 subgroup (r = -0.29, p = 0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: